HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma

• Main Authors: Tao Li (Author), Ling Liu (Author), Li Li (Author), Xiaoxuan Yao (Author), Xiaoyuan Hu (Author), Jiaxing Cheng (Author), Zhenpu Chen (Author), Jiyin Guo (Author), Ruilei Li (Author), Chunlei Ge (Author), Marie Chia-Mi Lin (Author), Hong Yao (Author)
• Format: Book
• Published: MDPI AG, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The combination of anti-angiogenesis agents with immune-checkpoint inhibitors is a promising treatment for patients with advanced hepatocellular carcinoma (HCC); however, therapeutic resistance caused by cancer stem cells present in tumor microenvironments remains to be overcome. In this study, we r...